EWM
CORT icon

Executive Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Executive Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$7.88M Buy
156,394
+95,800
+158% +$5.02M 0.62% 51
2024
Q3 		$2.8M Buy
+60,594
New +$2.15M 0.22% 98
2024
Q2 		– Sell
-140,690
Closed -$3.62M – 146
2024
Q1 		$3.62M Buy
140,690
+115,690
+463% +$2.73M 0.32% 79
2023
Q4 		$812K Hold
25,000
– – 0.08% 124
2023
Q3 		$681K Buy
+25,000
New +$724K 0.07% 129

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Executive Wealth Management's CORT Position: Q4 2024 in Review

Executive Wealth Management increased its Corcept Therapeutics (CORT) stake by 158% in Q4 2024, buying an estimated $5.02M and bringing the position to 156,394 shares worth $7.88M. The position accounts for 0.62% of the portfolio, ranked #51.

Executive Wealth Management first reported a position in CORT in Q3 2023 and has held it in 5 quarters since. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

  • Executive Wealth Management held 156,394 shares of Corcept Therapeutics worth $7.88M as of Q4 2024.
  • Executive Wealth Management bought 95,800 Corcept Therapeutics shares in Q4 2024, an estimated $5.02M.
  • Corcept Therapeutics made up 0.62% of Executive Wealth Management's portfolio in Q4 2024, its #51 holding.
  • Executive Wealth Management first reported a position in Corcept Therapeutics in Q3 2023 and has held it in 5 quarters since.
  • 367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Executive Wealth Management's 13F filing for Q4 2024, filed 13 Feb 2025.